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Highlights  
 Chitosan (CS) chloride complexes ovalbumin (OVA) model antigen into nanoparticles 
 CS:OVA nanoparticles displayed favourable OVA release and no notable cytotoxicity 
 CS:OVA nanoparticles markedly enhanced antigen permeability in Caco-2 
monolayers 
 Mucosal immune response was weak; systemic immune response not apparent in 
mice  
 Cell monolayers antigen uptake not predictive of in vivo systemic immune response  
 
 
 
Abstract  
This study compared in vitro and in vivo antigen delivery effects of ultrapure chitosan (CS) 
chloride. CS nanoparticles were formulated to incorporate ovalbumin (OVA) as a model 
antigen and characterised for size, charge, OVA complexation and release. The effect of 
CS:OVA nanoparticles on cell viability, epithelial tight junctions and transepithelial permeation 
of OVA was tested on Caco-2 monolayer in vitro intestinal model. The system’s ability to elicit 
immune responses was subsequently tested in vivo. The work confirmed that CS complexes 
with OVA into nano-size entities. Nanocomplexes displayed favourable delivery properties, 
namely OVA release and no notable cytotoxicity. CS:OVA markedly enhanced antigen 
delivery across Caco-2 monolayers. However, the system did not elicit notable in vivo 
immune responses (some mucosal response was apparent) following oral delivery. The study 
highlights that a clear effect on antigen permeability across epithelial monolayers in vitro may 
predict the in vivo mucosal but not systemic immune response following oral delivery.  
 
Keywords  
Absorption enhancement; Chitosan; Chitosan nanoparticles; Oral vaccine delivery; 
Ovalbumin 
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Introduction  
Mucosal vaccination is the most effective route to induce a local protective immune response 
against infections originating at mucosal surfaces (Shalaby, 1995). The oral route offers 
potential for convenient administration of vaccines that achieve mucosal immune response 
following specific targeting of antigens to the gut associated lymphoid tissue (GALT). The 
gastrointestinal tract, however, is an environment that presents several barriers to vaccine-
mediated production of mucosal immune response. The presence of these barriers 
necessitates the use of appropriate delivery systems to ensure antigen protection from 
degradation, enhanced uptake/absorption and immune cell activation.    
 
Chitosan (CS), a polymer derived from chitin, has become one of the most researched 
polymers in drug delivery due to its promising utility as an absorption enhancer. The capacity 
of CS to facilitate drug delivery across mucosal surfaces is attributed to its mucoadhesive 
properties and its ability to open the epithelial tight junctions, as structures that keep adjacent 
epithelial cells in close proximity with one another. A number of studies by our group 
(Vllasaliu et al., 2012; Vllasaliu et al., 2010; Vllasaliu, Fowler, & Stolnik, 2014) have 
convincingly confirmed CS’s ability to promote macromolecular absorption in vitro across 
intestinal and airway epithelial models.  
 
CS and its soluble derivate, N-trimethyl chitosan (TMC), in both solution or particulate forms, 
have demonstrated clear potential for improved oral delivery of peptide and protein drugs 
(Chen et al., 2008; Sandri et al., 2007; van der Merwe, Verhoef, Verheijden, Kotze, & 
Junginger, 2004; Vllasaliu et al., 2012). CS has also been explored widely as a component of 
particulate delivery systems with the potential to enable clinically effective oral administration 
of vaccines (Guo, Li, Lin, & Zhang, 2016; Li et al., 2017; Vera Ramirez, Sharpe, & Peppas, 
2017). This is because antigen encapsulation in particles is considered to be a key strategy in 
overcoming the hurdles of poor antigen immunogenicity and degradation in the 
gastrointestinal tract (Soares, Jesus, & Borges, 2017). However, it is not entirely clear 
presently whether the proven absorption enhancing property of CS is useful in promoting 
antigen uptake and a therapeutically relevant immune response following oral delivery of 
antigens.  
 
M-cells in the follicle-associated epithelium (FAE) of intestinal Peyer’s patches, which actively 
sample the gut lumen transporting antigens to the underlying mucosal lymphoid tissue for 
processing and initiation of an immune response, are an obvious target in oral vaccine 
delivery (Slutter et al., 2009). It has been shown that nanoparticles are actively taken up by 
the FAE through M-cells (Beloqui, Brayden, Artursson, Preat, & des Rieux, 2017). Therefore, 
it has been suggested that the use of a nanoparticulate delivery system may function as a 
double-edged sword, increasing the uptake into epithelium and subsequently the uptake into 
antigen presenting cells (APCs) (Slutter et al., 2009). Whether an enhanced transepithelial 
permeation of macromolecules (e.g. antigens), which can be afforded by CS nanoparticles, is 
translated into an improved immune response in vivo is not clear.  
 
This work set out to compare the in vitro and in vivo oral vaccine delivery effects of CS 
chloride (213 kDa average molecular weight) as a CS salt that has consistently shown 
absorption enhancing properties in vitro in our previous work (Casettari et al., 2010; Vllasaliu 
et al., 2012; Vllasaliu et al., 2010). CS nanoparticles were formulated via a commonly 
employed ionic gelation method (Vllasaliu et al., 2010), incorporating ovalbumin (OVA) as a 
model antigen. Nanoparticles were then characterised for size, charge and ability to 
incorporate and release the model antigen cargo. The effect of CS:OVA nanoparticles on cell 
viability, epithelial tight junctions and transepithelial permeation of the antigen was tested in 
Caco-2 cell monolayers as an in vitro intestinal model. The system’s ability to produce 
immune responses was subsequently tested in vivo.  
 
Materials and Methods 
Materials 
Different types of ovalbumins were used: fluorescein isothiocyanate (FITC)-labelled 
ovalbumin (OVA) (FITC-OVA, 3 moles dye/mole), purchased from Thermo Fisher Scientific 
(USA); non-labelled OVA, purchased from Sigma-Aldrich (UK); and endotoxin-free OVA 
(EndoGrade®), purchased from Cambridge Bioscience (UK). Ultrapure CS chloride of 213 
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kDa average molecular weight (‘Protasan UP CL 213’) was obtained from Novamatrix 
(Norway). Tripolyphosphate (TPP), Triton X-100, 2-(N-morpholino)ethanesulfonic acid (MES), 
paraformaldehyde and Fluoroshield with DAPI were all purchased from Sigma-Aldrich (UK). 
Caco-2 cells were attained from the European Collection of Cell Cultures (ECACC) and used 
between passages 57-88. Hank’s Balanced Salt Solution (HBSS) (with sodium bicarbonate, 
without phenol red), phosphate buffered saline (PBS) tablets and trypsin were purchased 
from Sigma-Aldrich (UK). Transwell permeable inserts of 12 mm diameter and 0.4 µm pore 
size were obtained from Costar (USA). 3-(4,5-dimethylthiazol-2-yl)-5(3-
carboxymethonyphenol)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) reagent, which is 
commercially known as  'CellTiter 96 AQueous One Solution Cell Proliferation Assay', was 
obtained from Promega (USA). For the lactate dehydrogenase (LDH) assay, the 'Pierce LDH 
Cytotoxicity Assay Kit' (Thermo Scientific, USA) was used. Goat, anti-mouse IgG H & L 
(Horse Radish Peroxidase, HRP) pre-absorbed was purchased from Abcam (UK). Goat, anti-
mouse IgA-HRP was obtained from Invitrogen (UK) and goat, anti-mouse IgG1-HRP was 
sourced from Southern Biotech (USA). 
 
Nanoparticle formulation and characterisation 
CS:OVA nanoparticles were prepared at different ratios. First, stock solutions of 2 mg/ml CS 
and 2 mg/ml OVA were prepared in dH2O. As a chloride salt, the specific CS used in this work 
dissolved in dH2O with continuous stirring in approximately 20 minutes. Once dissolved, CS 
was mixed with OVA, creating a 1 mg/ml concentration (both CS and OVA, i.e. 1:1 mass 
ratio). TPP solution (1 mg/ml in dH2O) was then added dropwise using a syringe with 
continuous stirring. TPP was added slowly until the solution appeared opalescent, indicating 
the formation of nanoparticles. Unlabelled OVA was used for nanoparticle characterisation, 
TEER and cytotoxicity studies, while FITC-OVA was employed in system fabrication for 
permeability studies.  
 
Nanoparticles were characterised for size and surface charge. Size was characterised by 
nanoparticle tracking analysis (NTA) using a Nanosight LM10 HS instrument (Malvern, UK). 
Following formulation, CS:OVA nanoparticles were diluted in dH2O or Hank’s Buffered Salt 
Solution (HBSS), supplemented with 2-(N-morpholino)ethanesulfonic acid (MES) buffer at 10 
mM to create a pH of 6.0. The latter was done to replicate the biological solution used in cell 
studies.  
 
Zeta potential measurements were carried out for nanoparticles with and without OVA, both in 
dH2O and HBSS to compare the effect of OVA on CS nanoparticle surface charge, as well as 
the effect of the biological buffer (high ionic strength) on the system’s surface charge. Zeta 
potential was measured using a Zetasizer Nano ZS instrument (Malvern, UK). 
 
Antigen complexation and release form nanoparticles 
CS:OVA nanoparticles (1:1 mass ratio; 1 mg/ml) were prepared as described earlier, using 
FITC-OVA. Fluorescence of the resulting nanoparticle suspension was measured using a 
Tecan Infinite M200 Pro plate reader (Tecan Group ltd, Switzerland) using excitation and 
emission wavelengths of 488 nm and 520 nm, respectively. 1 ml of 1 mg/ml heparin in dH2O 
or dH2O (control) was applied to the CS:OVA nanoparticle suspension and the mixture was 
incubated for 30 minutes at room temperature. Thereafter, the mixture was processed for 
ultrafiltration using Vivaspin centrifugal concentrator tubes of 1,000 kDa molecular weight cut-
off (MWCO), using centrifugation time and force specified by the manufacturer. Following 
centrifugation, the fluorescence of the filtrate was measured and compared to fluorescence 
values prior to filtration.        
 
Cell culture  
Caco-2 cells were routinely maintained in 75 cm2 flasks at 37 °C, 5% CO2 and 95% relative 
humidity. Dulbeco's Modified Eagle's Medium (DMEM) was used as the culture medium; this 
was supplemented with antibiotic and antimycotic solution (10,000 units of penicillin, 10 mg 
streptomycin and 25 µg amphotericin) and 10% v/v foetal bovine serum (FBS, European 
origin). Culture medium was replaced every two to three days.  
 
For use as polarised monolayers modelling the intestinal epithelium, Caco-2 cells were 
initially detached from flasks using trypsin and seeded on 12-well Transwell permeable 
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inserts at 1x105 to 2x105 cells per 1.1 cm2 insert. Cells were then cultured for 21 days, with 
regular replacement of culture medium (every two to three days).  
 
Cell toxicity studies  
MTS assay. Caco-2 cells were seeded on a clear 96-well plate and incubated for 24 hours 
prior to the assay. Samples were applied at different concentrations in HBSS. A 10% v/v 
solution of Triton X-100 in HBSS was used as a positive control and HBSS as a negative 
control. Samples were applied for three hours, following which the assay was conducted 
according to manufacturer’s instructions, with absorbance measurements at 490nm using a 
Tecan Infinite M200 Pro plate reader.     
 
The relative cell metabolic activity (%) was calculated using the following equation:  
 
Relative metabolic activity  =
𝑆−𝑇
𝐻−𝑇
× 100 
 
Where: S is the absorbance of cells incubated with tested samples; T is the absorbance of 
cells incubated with Triton X-100; H is the absorbance of cells incubated with HBSS. 
 
LDH assay. Caco-2 cells were seeded on a clear 96-well plate and cultured for 48 hours 
before the assay. Samples were applied dissolved in HBSS, with 10% v/v Triton X-100 in 
HBSS and HBSS alone used as a positive and negative controls, respectively. Samples were 
applied to the cells for three hours and the assay performed following the manufacturer’s 
instructions, with absorbance measured at 490 nm by a Tecan Infinite M200 Pro plate reader.     
 
LDH release was calculated as a percentage relative to the controls, using the following 
equation:  
 
Relative LDH release = 
𝑆−𝐻
𝑇−𝐻
 𝑋100 
 
Where: S is absorbance of the tested samples; H is absorbance of HBSS; T is absorbance of 
Triton X-100. 
 
Transepithelial electrical resistance studies 
Transepithelial electrical resistance (TEER) studies were conducted to measure the tight 
junction-opening effect of CS:OVA. Caco-2 cell monolayers were cultured on Transwell 
inserts for 21 days. Culture medium was initially replaced with HBSS and the cells placed in 
an incubator for 40-45 minutes to allow adjustment to the change in environment. TEER was 
measured before sample application (‘time zero’). CS:OVA samples were then applied to the 
apical side of cell monolayers at different concentrations, in HBSS. TEER was subsequently 
recorded every 30 minutes for three hours, followed by a final ‘reversibility measurement’, 24 
hours post-sample application (samples were removed after three hours incubation and cells 
incubated with the culture medium until the final TEER measurement).    
 
OVA permeability study 
Caco-2 monolayers displaying a minimum TEER of 900 Ωcm2 were considered suitable for 
the permeability studies. TEER measurements were taken before the permeability study to 
confirm the polarity and integrity of the cell monolayers. Culture medium was replaced with 
HBSS and cells incubated at 37°C/5% CO2 for 40-45 minutes to acclimatise to HBSS. Test 
samples, consisting of CS:OVA (FITC-OVA) nanoparticles were then applied on the apical 
side of cell monolayers. CS:OVA translocation across the cell monolayers was determined by 
sampling the basolateral solution (100 µl) at regular intervals (every 30 min for 3 hours), with 
replacement of the sampled solutions with HBSS. CS:OVA translocation was determined by 
quantifying FITC-OVA through fluorescence measurements (488 nm excitation and 520 nm 
emission).  
 
Permeability is expressed as the apparent permeability coefficient (Papp), which was 
calculated using the following equation: 
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𝑃𝑎𝑝𝑝 = (
∆Q
∆t
)  x (
1
A × Co
) 
Papp, apparent permeability (cm/s); ΔQ/Δt, permeability rate (amount of FITC-OVA traversing 
the cell layers over time); A, diffusion area of the layer (cm2); C0, apically added FITC-OVA 
concentration. The experiment was conducted in triplicates. 
 
In vivo studies 
Female BALB/c mice (6-8 weeks old) were obtained from Charles River Ltd. All animal 
procedures were conducted in accordance with the Home Office (scientific procedures) Act 
1986). Mice were immunised weekly on four occasions at days 0, 7, 14 and 21 by oral 
gavage with 200 µg of free OVA, OVA and 15 µg cholera toxin (CTX), or with CS:OVA 
nanoparticles in sodium bicarbonate pH 8.2 (all in 8.5% sodium bicarbonate). Mice were 
terminally bled on day 35. Intestinal washes were prepared by removing the small intestine 
and washing it with a protein degradation inhibition solution (ethylenediaminetetraacetic acid 
(EDTA), sodium azide, trypsin inhibitor, iodoacetic acid and phenylmethylsuphonyl fluoride 
(PMSF)), obtained from Sigma-Aldrich Ltd, UK.  
 
ELISA quantification of IgG and IgA. Endograde OVA (endotoxin free) was diluted to 10g/ml 
in carbonate buffer at pH 8.2 and transferred into 96-well plates (100 µl/well). Plates were 
incubated at 37 °C for 90 min and then at 4 °C overnight. OVA was then aspirated and the 
plates washed and subsequently blocked with the assay diluent (1% w/v bovine serum 
albumin (BSA), 0.3% v/v Tween 20 and 0.01M EDTA in PBS) at 37 °C for 30 min. Plates 
were then washed and 200 µl of immune mouse sera (diluted 1:50) added to the first column; 
samples were then serially diluted across the plate (for IgA determination, intestinal washes 
were tested for IgA antibodies at a single 1:2 dilution). Samples were incubated for 90 min at 
room temperature and the plate washed. Goat, anti-mouse IgG-HRP antibody (diluted 1:3000 
in assay diluent) or goat, anti-mouse IgA-HRP (diluted 1:2000) were applied (100 µl/well) and 
the plate incubated at room temperature for 90 min. Plates were then washed and 100 µl of o-
Phenylenediamine dihydrochloride (OPD) peroxidase substrate (Sigma-Aldrich Ltd) applied 
(in a dark environment) for 20 min. The reaction was then stopped with hydrochloric acid and 
sample absorbance measured at 492 nm. 
 
Each sample/dilution was tested in duplicates and data are presented as mean end point titre 
for IgG (reciprocal of serum dilution giving optical density > mean blank+2 standard deviation) 
and as mean optical density for the IgA response. 
 
Statistical Analysis 
Statistical comparisons for nanoparticle characterisation, toxicity assays, TEER and 
permeability studies were performed using a Students t-test for two groups and ANOVA in 
multiple group comparisons. Statistical analysis for ELISA data was performed using the 
Mann Whitney U test. p values of <0.05 were considered statistically significant. 
 
Results  
Nanoparticle characterisation 
Figure 1 reveals size and surface charge data for CS:OVA nanoparticles (1:1 mass ratio) in 
HBSS (Figure 1A) and in dH2O (Figure 1B). The data highlight a lower mean and mode of 
138.1 and 126.1 nm, respectively, in HBSS compared to dH2O (411.3 and 196.5 nm, 
respectively). The data also show that the nanoparticles sample is relatively monodisperse in 
HBSS, while in dH2O particulate species of multiple sizes are present. 
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A)         B) 
 
 
 
Figure 1. Size characterisation of CS:OVA nanoparticles in Hank’s Balanced Salt Solution (HBSS) (A) 
and dH2O (B), using nanoparticle tracking analysis (NTA) with a Nanosight LM10 HS instrument. 
 
 
 
Table 1 compares the zeta potential (surface charge) of CS:OVA nanoparticles against CS 
nanoparticles (no OVA) in HBSS and dH2O. Nanoparticles displayed a lower surface charge 
in HBSS compared to dH2O, specifically +9.68 mv and +37.9 mv, respectively. The zeta 
potential of CS:OVA systems (+9.68 mv) is lower compared to CS only nanoparticles (+13.1).  
 
Table 1. Zeta potential comparison of CS:OVA nanoparticles against CS nanoparticles in HBSS and 
dH2O.  
Sample Zeta potential (mv) 
CS:OVA nanoparticles in HBSS +9.68 
CS nanoparticles in HBSS +13.1 
CS:OVA nanoparticles in dH2O +37.9 
CS nanoparticles in dH2O +41.9 
 
 
Complexation and release studies were carried out to determine the ability and efficiency of 
CS and OVA to complex into CS:OVA nanoparticles. Figure 2 shows the release of OVA from 
formulated CS:OVA nanoparticles (FITC-OVA was used to enable quantitation, but referred to 
‘OVA’). The fluorescence of 1:1 mass ratio of the systems was measured before and after 
FITC-OVA release, which was triggered by exposure to heparin, followed by membrane 
ultrafiltration (using membranes permeable to the released FITC-OVA, but not CS:OVA 
nanoparticles). The fluorescence intensity of CS:OVA nanoparticle filtrate not treated with 
heparin is dramatically lower, 499, compared to 6904 before filtration. This suggests that 
some, namely 6.9% OVA (calculated by converting fluorescence into amount) is lost following 
filtration of CS:OVA nanoparticles, most likely attributed to excess OVA unincorporated into 
nanoparticles. However, 93.1% of OVA remains incorporated in CS:OVA nanoparticles with 
1:1 mass ratio and these did not permeate the filters due to the inability of nanoparticles to 
permeate membranes with 1000 kDa molecular weight cut off (MWCO). On the other hand, 
with samples exposed to heparin to induce OVA release and then filtered, the fluorescence 
intensity of the filtrate was remarkably higher compared to that of filtrate where heparin 
treatment was omitted. In fact, fluorescence intensity in this scenario was only slightly lower 
to that pre-filtration (6232.16 vs 7175), suggesting that 86.8% of OVA was released from 
CS:OVA nanocomplexes (and permeation through 1000 kDa MWCO ultrafiltration 
membranes) following exposure to heparin.    
 
	
Mean 411.3 nm 
Mode 196.5 nm 
SD 195.7 nm 
	
Mean 138.1 nm 
Mode 126.1 nm 
SD 35.2 nm 
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Figure 2. Release of FITC-OVA from chitosan:OVA nanoparticles, tested following exposure to heparin 
and membrane ultrafiltration. Data shown as the mean ± SD (n=3).  *** signifies P=0.0002; * signifies P= 
0.0356. 
 
 
Cell toxicity studies  
Figure 3A shows CS:OVA nanoparticle toxicity, as determined in Caco-2 cells via the MTS 
assay. The data show that the highest concentration of nanoparticles (0.1 mg/ml) resulted in 
a reduction of relative cell viability to approximately 62% (relative to negative control, HBSS, 
assumed to produce 100% viability and positive control, Triton X-100, assumed to induce 
total cell death and therefore 0% viability). As CS:OVA nanoparticle concentration decreased, 
the effect on relative cell viability diminished, although the difference between step increases 
in concentration was not statistically significant. CS:OVA nanoparticle concentration of 0.05 
mg/ml displayed a reduction of relative cell viability to 85% and two lowest concentrations 
induced a small reduction of relative cell viability to 94-95%.  
 
Membrane toxicity studies were also conducted for CS:OVA nanoparticles via the LDH assay. 
This assay measures the leakage of an intracellular enzyme, lactate dehydrogenase (LDH), 
which occurs upon plasma membrane damage. As a measure of cell membrane integrity, the 
LDH assay is important to study the toxicity of positively charged systems such as CS. The 
data in Figure 3B clearly show that CS:OVA nanoparticles were associated with low levels of 
LDH release (between 2-4%) in Caco-2 cells, with the difference in effect between 
concentrations not statistically significant. 
 
A)            B) 
 
 
Figure 3. Toxicity of chitosan:ovalbumin (CS:OVA) nanoparticles. A) Effect of different concentrations of 
CS:OVA nanoparticles on Caco-2 relative viability, as determined by the MTS assay. Data shows the 
mean ± SD (n = 6). B) Effect of different concentrations of CS:OVA nanoparticles on lactate 
dehydrogenase (LDH) release. Hank’s Balanced Salt Solution (HBSS) was used as a negative control 
and Triton X-100 as a positive control for cell death. Data shows the mean ± SD (n = 4).  
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Transepithelial electrical resistance studies 
Figure 4 shows the effect of CS:OVA nanoparticles on Caco-2 cell monolayer TEER. Different 
concentrations of the systems were applied to the cells, as well as OVA itself as a control. All 
concentrations of CS:OVA nanoparticles caused a decrease in TEER, although application of 
OVA alone was in fact associated with the largest drop in TEER, by approximately 55%. 
However, CS:OVA nanoparticle samples caused a steeper (faster) reduction in TEER 
compared to OVA. In this experiment, TEER was partially reversible after 48 hours with 
CS:OVA samples and fully reversible with OVA.  
 
 
Figure 4. Effect of different concentrations of chitosan:ovalbumin (CS:OVA) nanoparticles and OVA at 
0.1 mg/ml on Caco-2 monolayer transepithelial electrical resistance (TEER). Data shows the mean ± SD 
(n = 3). 
 
 
OVA permeability study 
Apical-to-basolateral permeation of FITC-OVA following application of CS:OVA nanoparticles 
to Caco-2 monolayers is shown in Figure 5. Note that only FITC-OVA was quantified in these 
studies (through fluorescence measurements) and it is not possible to state whether FITC-
OVA crossed the cell monolayers complexed in CS:OVA nanoparticles or whether it was 
released en route. FITC-OVA permeability following application of CS:OVA nanoparticles was 
notably greater, specifically 4.5 times higher compared to FITC-OVA alone.  
 
  
 
Figure 5. Ovalbumin (OVA) permeability following application of chitosan:ovalbumin (CS:OVA) 
nanoparticles at 0.1 mg/ml and comparison with OVA applied in solution (0.1 mg/ml). Fluorescently 
labelled ovalbumin (FITC-OVA) was used in both cases. P=0.0036. Data shows the mean ± SD (n = 3).  
 
 
In vivo studies 
The ability of CS-encapsulated OVA to induce systemic (IgG) and mucosal (IgA) immune 
responses following oral immunisation was evaluated by immunising mice four times at 
weekly intervals with CS:OVA nanoparticles, OVA alone or with OVA-CTX as controls. Data 
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presented in Figure 6A show that sera samples from mice immunised with OVA alone had 
very low level of anti-OVA IgG antibodies (mean titre = 76) and the presence of CTX as an 
adjuvant increased the response significantly (mean titre 922; p<0.01), with 3/5 mice having 
antibody level well above the OVA control group. However, immunisation with CS-OVA failed 
to increase the serum anti-OVA IgG response above the low level induced by OVA alone 
(mean titre = 172; p>0.05).  
 
Similar to systemic IgG, free OVA induced a weak IgA response (Figure 6B) in intestinal 
washes (mean OD = 0.59) and mice immunised with CS:OVA had much higher level of anti-
IgA response (mean OD =1.3; p<0.01). The increase was equal to that induced in mice 
immunised with OVA-CTX (mean OD = 1.3), indicating the adjuvanticity of CS for the 
induction of mucosal antibody response. The level of IgG and IgA response varied between 
low, medium and high amongst animals within the same group.  
 
A) 
 
B) 
 
Figure 6. Anti-OVA antibody response following oral administration of CS:OVA nanoparticles in mice. A) 
Serum IgG response. B) Intestinal washes IgA response.  
 
  
AC
CE
PT
ED
 M
AN
US
CR
IPT
 11 
Discussion  
This work used a specific CS molecule (ultrapure CS chloride salt, average molecular weight 
213 kDa), which has previously consistently shown substantial absorption-enhancing effects 
by our group, to fabricate nanocomplexes with OVA as a model antigen. The aim of the study 
was to establish whether macromolecular absorption enhancement, as tested in the Caco-2 
in vitro intestinal epithelial monolayer model, is translated into an induction of immune 
response in vivo.   
 
CS:OVA nanoparticles fabricated in this work displayed diameters below 200 nm and a 
positive zeta potential at 1:1 mass ratio (Figure 1 and Table 1, respectively). This is similar to 
previous work reporting CS:OVA nanosystems with size ranging from 83.66 nm (Wen, Xu, 
Zou, & Xu, 2011) to 350 nm (Amidi et al., 2006). The lower surface charge (zeta potential) of 
CS:OVA nanoparticles compared to CS only systems is expected due to OVA’s negative 
charge (reported zeta potential of -20 to -25 mV (Niu et al., 2014) at pH 6.0-6.7), attenuating 
CS’s positive surface charge. The observed zeta potential values of CS:OVA nanoparticles of 
37.9 mV and 9.68 mV in dH2O and HBSS, respectively, are comparable to other studies, 
which reported ranges between 7.88-25 mV (Jana, Maji, Nayak, Sen, & Basu, 2013; 
Schrøder, Long, & Olsen, 2014). 
 
Testing the ability of the carrier system to release the antigen payload is important as the 
incorporated antigen cargo must be available for immune-inducing effect. OVA release from 
CS:OVA nanoparticles was tested by the addition of a highly negatively charged molecule, 
heparin. This was based on competitive electrostatic interaction of heparin (which has a 
significantly higher negative charge than OVA) with the positively charged CS, releasing OVA 
from the nanocomplexes in the process. Following incubation with heparin and ultrafiltration, 
86.8% of OVA (FITC-labelled) was released from the complexes in the filtrate, suggesting a 
high degree of antigen dissociation from nanocomplexes (Figure 2).  
 
The CS:OVA nanoparticles fabricated in this work did not display appreciable toxicity to Caco-
2 cells, as confirmed by MTS and LDH assays. The MTS cell viability data (Figure 3A) 
showed that the highest concentration of CS:OVA nanoparticles reduced Caco-2 viability 
between 15 and 38%, whereas the lower concentrations did not significantly reduce cell 
viability. The relative absence of cytotoxicity is also confirmed by the LDH assay, whereby 
CS:OVA nanoparticles at all tested concentrations did not significantly increase LDH release 
(below 5% in all cases). The relative absence of cytotoxicity with CS:OVA is likely to be 
helped by the presence of OVA in the system and the consequent reduction in the positive 
surface charge of nanoparticles, as demonstrated by zeta potential reduction. This is because 
charge dependency of nanoparticulate toxicity is a well demonstrated effect (Casettari et al., 
2010; Naha, Davoren, Lyng, & Byrne, 2010; Schaeublin et al., 2011). 
 
TEER experiments were conducted to ascertain whether CS:OVA nanoparticles were 
capable of disrupting the intestinal epithelial barrier through tight junction opening as this 
biological effect has been demonstrated convincingly for CS by many groups. TEER 
reduction was observed following sample application, although the same observation was 
also apparent for OVA solution at concentration equivalent to that present in nanoparticles 
(0.1 mg/ml). As a result, it is not clear whether CS:OVA nanoparticles exert a tight junction-
modulating effect, although the pattern of TEER reduction was different with CS:OVA 
nanoparticles compared to OVA solution control. With all the concentrations of CS:OVA 
nanoparticle samples, the TEER decrease was reversible, which is another indication of non-
toxicity.  
 
CS nanoparticles have previously been shown to produce a clear effect on tight junctions, 
with a prior study by our group demonstrating a significant reduction of TEER (by more than 
80%) in Caco-2 cell monolayers (Vllasaliu et al., 2010). It is possible that CS:OVA 
nanoparticles in this work did not offer a dramatic reduction in Caco-2 monolayer TEER due 
to surface charge reduction of the systems (from OVA presence). Such observation was 
reported by Sadeghi et al. (Sadeghi et al., 2008), showing that nanoparticles consisting of CS 
and its quaternary ammonium derivatives loaded with insulin were less effective in facilitating 
paracellular transport across Caco-2 cell monolayers compared to the corresponding free 
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polymers and arguing that the reduced charge density at nanoparticle surface, compared to 
the soluble form of CS, was responsible for this finding. 
 
Permeability studies were performed to determine whether OVA, as a model antigen 
complexed with CS into nanoparticles, permeated across the intestinal epithelium 
(represented by the Caco-2 model). Data demonstrate that OVA permeability is 5-fold higher 
following application of CS:OVA compared to the equivalent concentration of OVA solution. It 
must be noted that due to the nature of the experimental procedure, whereby fluorescently-
labelled OVA was quantified, it is not possible to establish whether CS:OVA nanoparticles 
permeated the cell monolayers or if OVA dissociated from the nanoparticles, before or during 
the transit process. The increase in OVA permeability across Caco-2 monolayers is notable 
considering the lack of clear effect on epithelial tight junctions. The mechanism responsible 
for this is therefore more likely to relate to nanoparticle uptake by, and translocation across, 
Caco-2 cells rather than paracellular transit. The relatively small size of CS:OVA 
nanoparticles prepared in this work is likely to facilitate the cell uptake of nanoparticles.  
 
Following the demonstration of CS complexation with (and release of) OVA, a good overall 
toxicity profile and enhancement of OVA permeation across Caco-2 monolayers, the 
performance of the systems as mechanisms to promote oral vaccine delivery was evaluated 
in vivo. This is important as the in vitro outcome of many drug formulation systems is often 
not reproduced in vivo. In case of systems designed to deliver the therapeutic payload across 
the mucosal surfaces, current in vitro epithelial models may not faithfully represent the more 
complex mucosal surfaces, which consist of multiple cell types and have additional 
components that may act as important barriers to particulate delivery, with mucus and the 
basement membrane being obvious examples.  
 
Induction of mucosal immune response following oral immunisation necessitates the use of a 
potent adjuvant to overcome induction of tolerance (Shalaby, W. S.1995). The immunising 
antigens need to reach the gut associated lymphoid tissues GALT (e.g. Peyer’s patches) to 
be able to induce a mucosal antibody response and the draining lymph nodes and, 
subsequently, the primary lymphoid organs for induction of systemic immune response. It is 
clear from our results that oral immunisation with CS-encapsulated OVA induced a 
substantial mucosal IgA response, which was similar to the response induced by OVA in the 
presence of the potent adjuvant, CTX. Interestingly, CS:OVA failed to induce a systemic IgG 
response, while the co-administration of OVA and CTX was able to induce a substantial IgG 
response in 3 out of 5 mice. This could be attributed to the large size of the CS:OVA particles 
(mean 138 nm), which may be able to reach the local mucosal lymphoid tissues, but probably 
failed to reach the draining lymph nodes and the central lymphoid organs subsequently, 
which is necessary for the induction of systemic immune response. It is also possible that the 
immunisation regimen used does not favour induction of systemic IgG as only 3/5 animals 
had a good level of IgG response after OVA+CTX immunisation and further studies are 
needed to address this point. Interestingly, we have recently shown in our lab that induction of 
a substantial systemic IgG response to orally delivered antigens requires five consecutive 
immunisations, even in the presence of a potent adjuvant, such as CTX.  
 
Several studies reported successful induction of systemic and mucosal antibody response 
following oral immunisation with CS-encapsulated antigens. For example, a study by Biswas 
et al. (Biswas, Chattopadhyay, Sen, & Saha, 2015) used BALB/b mice in oral immunisation 
studies using alginate-coated CS nanoparticles encapsulating measles antigen, prepared via 
ionotropic gelation using tripolyphosphate. The study found the presence of measles specific 
IgG and IgA in the serum and an increase in IgA secretion from the intestinal lavages for low 
molecular weight alginate-coated CS nanoparticles. Another study utilising dual tetanus and 
diphtheria toxoid-loaded, stable CS-glucomannan nanoassemblies demonstrated humoral, 
mucosal and cellular immune response by eliciting complete protective levels of anti-tetanus 
toxoid and anti-diphtheria toxoids antibodies (Harde, Siddhapura, Agrawal, & Jain, 2015). 
However, direct comparisons between this work and literature reports are not possible 
considering the many variables, such as different CS-based systems, incorporated antigens 
and immunisation regimens.  
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With regards to the use of in vitro models for prediction of oral vaccine delivery, the 
importance of reliably modelling FAE is appreciated. FAE contains both enterocytes and 
specialised M cells, which are key in the process of luminal sampling and transport of 
antigens to lymphoid tissue cells beneath, initiating the mucosal immune response (Kiyono & 
Fukuyama, 2004). In vitro, human M cell-like co-culture models are increasingly being used to 
investigate the uptake of nanoparticle-delivered antigens (des Rieux et al., 2007; Gullberg et 
al., 2000; Kerneis, Bogdanova, Kraehenbuhl, & Pringault, 1997; Kesisoglou, Schmiedlin-Ren, 
Fleisher, & Zimmermann, 2010). Although these models are labour-intensive and there is 
high inter-laboratory variability, partly because of different approaches used to establish filter-
grown Caco-2/Raji B cell co-culture systems (Ahmad, Gogarty, Walsh, & Brayden, 2017), the 
use of these constructs is more appropriate in studies aiming to develop delivery systems for 
oral vaccine delivery. However, even in those situations one must exercise caution as these 
models do not represent the combination of physicochemical barriers present in the native 
mucosal tissue.   
 
It is nevertheless interesting that a notably enhanced antigen permeability across the Caco-2 
enterocyte system with CS:OVA nanoparticles was translated into an in vivo mucosal but not 
systemic immune response. This is particularly the case considering that compared with the 
Caco-2 monoculture used in the present study, M cell-like co-culture models are associated 
with increased particle translocation (Ahmad et al., 2017; Lai & D'Souza, 2008). An important 
conclusion from this study is that clear antigen absorption enhancement seen in vitro in the 
Caco-2 intestinal epithelial model, which has often been employed to study the potential of 
oral vaccine delivery systems, translates in mucosal but not systemic immune response 
following oral delivery in vivo.  
 
Conclusion  
This work confirmed the CS’s ability to complex a model antigen into nano-size entities. 
Although these systems show interesting effects in vitro, namely notable augmentation of 
antigen delivery across an intestinal epithelial monolayer model, this does not reliably predict 
in vivo systemic immune response following oral delivery.  
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